Prolia (Denosumab) Cost in Mississippi 2026: Pricing, Insurance, and Savings Options

What Does Prolia (Denosumab) Cost in Mississippi?

The average cash-pay price for a single 60 mg prefilled syringe of Prolia at Mississippi retail pharmacies sits at approximately $1 to 500 in 2026, matching Amgen's national list price. Because Prolia is administered once every six months, the annual cash cost for an uninsured patient is roughly $3,000.

That number can shift depending on where you fill the prescription. Hospital outpatient pharmacies in Jackson, Hattiesburg, and Gulfport may bill differently than standalone retail pharmacies. Buy-and-bill arrangements, where a physician purchases the drug and administers it in-office, can add injection fees ranging from $25 to $150 depending on the practice. Medicare Part B patients typically receive Prolia through buy-and-bill, with the drug reimbursed under HCPCS code J0897 at the Average Sales Price plus 6%.

A 2020 analysis published in the Journal of Bone and Mineral Research found that the annual per-patient cost of denosumab therapy in the United States averaged $3,128 when accounting for administration fees and monitoring labs [1]. Mississippi's costs track closely to this national figure. For patients paying entirely out of pocket, two injections per year plus two sets of monitoring labs (serum calcium, 25-hydroxyvitamin D, and renal function panels) bring the all-in annual cost to approximately $3,200 to $3,500.

The FREEDOM trial (N=7,868), published in the New England Journal of Medicine, demonstrated that denosumab 60 mg every six months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared to placebo over 36 months [2]. That efficacy profile is what drives coverage decisions for most commercial payers, even when the sticker price looks steep.

Does Mississippi Medicaid Cover Prolia?

It does not. As of 2026, Mississippi's Division of Medicaid does not include Prolia (denosumab) on its preferred drug list for osteoporosis treatment. This affects a significant population: Mississippi has one of the highest rates of Medicaid enrollment in the Southeast, with over 700,000 beneficiaries.

Patients on Mississippi Medicaid who need osteoporosis treatment are typically directed toward generic bisphosphonates first. Alendronate (generic Fosamax) at 70 mg weekly costs $4 to $15 per month through most Medicaid formularies and carries strong fracture-reduction evidence from the Fracture Intervention Trial [3]. Risedronate and ibandronate are also covered alternatives.

For Medicaid patients who have failed or cannot tolerate oral bisphosphonates, prescribers can submit a prior authorization request for Prolia. Approval is not guaranteed. The Mississippi Division of Medicaid requires documentation of bisphosphonate intolerance or contraindication (such as esophageal disorders, inability to remain upright for 30 minutes, or creatinine clearance below 30 mL/min, where bisphosphonates are contraindicated per FDA labeling) [4].

Zoledronic acid (Reclast), an intravenous bisphosphonate given once yearly, is sometimes a covered alternative for Medicaid patients who cannot take oral formulations. A single infusion costs Medicaid programs approximately $300 to $500 after rebates, making it a significantly cheaper option from the payer's perspective.

Which Insurance Plans Cover Prolia in Mississippi?

Most major commercial health insurers operating in Mississippi cover Prolia with prior authorization. This includes Blue Cross Blue Shield of Mississippi, UnitedHealthcare, Humana, Aetna, and Cigna plans sold through the Health Insurance Marketplace or employer-sponsored coverage.

Prior authorization criteria vary by plan but typically require at least one of the following: a T-score of -2.5 or lower on DXA scan, a history of osteoporotic fracture, or a 10-year FRAX score exceeding the National Osteoporosis Foundation's treatment threshold (20% for major osteoporotic fracture or 3% for hip fracture) [5]. Many plans also require documentation that the patient has tried and failed at least one oral bisphosphonate, though some waive this step-therapy requirement for patients with very high fracture risk.

Blue Cross Blue Shield of Mississippi, the state's dominant insurer with over 900,000 members, classifies Prolia as a specialty drug on most formulary tiers. Copays for specialty-tier drugs on BCBS MS plans typically range from $75 to $250 per fill, though high-deductible health plans may require the patient to meet the full deductible first.

Medicare Part B covers Prolia for eligible beneficiaries at 80% of the Medicare-allowed amount after the Part B deductible ($257 in 2026). The remaining 20% coinsurance can be covered by Medigap supplemental insurance. For a Medicare patient with a Medigap Plan G policy, the true out-of-pocket cost for each Prolia injection is often $0 after the annual deductible is met.

The Endocrine Society's 2020 clinical practice guideline for postmenopausal osteoporosis recommends denosumab as a first-line option for patients at high fracture risk, particularly those with very low T-scores (below -3.0) or recent fractures [6]. Referencing this guideline in prior authorization appeals can strengthen the case for coverage.

How Does the Amgen Savings Card Work in Mississippi?

Amgen offers the Prolia Complete savings card program for commercially insured patients. The card can reduce out-of-pocket costs to as little as $0 per injection, with a maximum annual benefit that Amgen adjusts periodically. Eligible patients must have commercial insurance that covers Prolia, cannot be enrolled in any federal or state healthcare program (Medicare, Medicaid, Tricare, VA), and must be residents of the United States.

Enrollment is straightforward. Patients or their healthcare providers can register at the Prolia Complete website or by calling the program's phone line. Once enrolled, the savings card is applied at the pharmacy or physician's office at the time of each injection. The card covers the difference between the patient's copay or coinsurance and $0, up to the program's annual cap.

There are limitations. The card does not work at every pharmacy, and some buy-and-bill arrangements may require manual claims submission to Amgen for reimbursement. Patients using 340B-priced drugs through federally qualified health centers are also ineligible. In Mississippi, where 20% of the population lives in designated Health Professional Shortage Areas, 340B pricing affects a meaningful number of patients receiving care at community health centers.

For patients who lack insurance entirely, Amgen's Safety Net Foundation provides free Prolia to qualifying individuals with household incomes at or below 300% of the federal poverty level. A single applicant earning $46,800 or less in 2026 would meet this threshold.

Is Compounded Denosumab Legal in Mississippi?

Yes. Mississippi permits licensed 503A compounding pharmacies to prepare denosumab formulations under the federal Drug Quality and Security Act (DQSA) framework. A 503A pharmacy compounds a prescription for an individual patient based on a valid prescriber order, which distinguishes it from 503B outsourcing facilities that produce larger batches without patient-specific prescriptions [7].

The practical availability of compounded denosumab in Mississippi is limited. Few 503A pharmacies in the state currently offer denosumab compounding because the drug is a monoclonal antibody, and producing biologic compounds requires specialized equipment, cold-chain handling, and sterile technique that most small compounding pharmacies lack. Patients interested in compounded denosumab should verify that any pharmacy they consider holds a current Mississippi Board of Pharmacy compounding license and maintains appropriate sterility testing protocols.

Cost is the primary motivator for seeking compounded biologics. However, the FDA has raised ongoing concerns about compounded versions of complex biologics, noting that compounded drugs are not FDA-approved and do not undergo the same rigorous testing for potency, purity, and sterility as commercially manufactured products [8]. The risk-benefit calculation is different for a biologic like denosumab than for a simple small-molecule compound.

Patients who discontinue denosumab, whether branded or compounded, face a well-documented rebound effect. The FREEDOM extension study showed that bone mineral density gains reversed within 12 to 24 months of stopping therapy, and multiple vertebral fractures occurred in some patients after discontinuation [9]. Any decision about switching to or from compounded formulations should account for this rebound risk.

Can I Get Prolia via Telehealth in Mississippi?

Mississippi law permits telehealth prescribing of Prolia. A physician licensed in Mississippi can evaluate a patient remotely, review DXA scan results and lab work, and write a prescription for denosumab without an in-person visit. The Mississippi State Board of Medical Licensure adopted permanent telehealth rules following the COVID-19 pandemic expansions, allowing established patient-provider relationships to be formed via synchronous audio-video encounters.

The prescription itself is only half the equation. Prolia requires subcutaneous injection by a healthcare professional. Most patients receive their injection at a physician's office, clinic, or infusion center. A telehealth visit can handle the clinical decision-making, lab review, and prescription, but the patient still needs to visit a physical location for the actual injection.

Some Mississippi home health agencies offer in-home injection services for patients with mobility limitations. The cost for a home health nurse visit for a single injection typically ranges from $75 to $150 in the Jackson metro area, in addition to the drug cost.

HealthRX offers telehealth consultations with physicians who can evaluate whether denosumab is appropriate based on your bone density results, fracture history, and overall health profile.

Mississippi-Specific Discount Programs and Assistance

Beyond the Amgen savings card, several programs can help Mississippi residents reduce the cost of Prolia.

Mississippi Drug Assistance Programs. The state does not operate a standalone pharmaceutical assistance program for osteoporosis drugs. However, the Mississippi Division of Aging and Adult Services can connect eligible seniors (age 60+) with federal programs like Medicare Extra Help (Low-Income Subsidy), which reduces Part D and Part B cost-sharing for qualifying beneficiaries.

Patient Advocate Foundation. This national nonprofit offers case management and co-pay assistance for patients with chronic diseases, including osteoporosis. Mississippi residents can apply through PAF's online portal. Approval is income-based and subject to fund availability.

NeedyMeds and RxAssist databases. These free online tools aggregate manufacturer and nonprofit assistance programs by drug name and state. Searching for "denosumab" or "Prolia" returns current programs with eligibility criteria and application links.

GoodRx and similar discount aggregators. While GoodRx coupons work well for generic medications, the discounts available for brand-name biologics like Prolia are typically modest, reducing the cash price by 5% to 15% at participating pharmacies. A GoodRx coupon might bring the $1,500 list price down to approximately $1,275 to $1,425 at select Mississippi pharmacies, which is meaningful but far less impactful than the Amgen savings card for insured patients.

How Prolia Compares to Other Osteoporosis Treatments in Mississippi

Cost is one variable. Efficacy, administration route, and insurance coverage all factor into the decision.

Generic alendronate at 70 mg weekly costs $4 to $15 per month and reduced vertebral fractures by 47% over three years in the Fracture Intervention Trial [3]. It is the cheapest option and is universally covered by Mississippi Medicaid and commercial plans. The tradeoff: GI side effects, the requirement to take it on an empty stomach while remaining upright, and contraindication in patients with low creatinine clearance.

Zoledronic acid (Reclast) at 5 mg IV once yearly costs $300 to $1,200 depending on the setting and insurance. The HORIZON-PFT trial (N=7,765) showed a 70% reduction in vertebral fractures and 41% reduction in hip fractures over three years [10]. It requires an infusion center visit but eliminates daily or weekly pill adherence. Mississippi Medicaid may cover it as an alternative to oral bisphosphonates.

Teriparatide (Forteo) at 20 mcg daily by self-injection costs approximately $3,500 per month at list price. It is an anabolic agent that builds new bone rather than simply slowing resorption. The label limits use to 24 months. Mississippi Medicaid does not routinely cover Forteo without extensive prior authorization.

Romosozumab (Evenity) at 210 mg monthly by subcutaneous injection costs approximately $2,100 per month for the 12-month treatment course. The ARCH trial showed it reduced vertebral fractures by 48% compared to alendronate at 24 months [11]. It carries a boxed warning for cardiovascular risk and is typically reserved for patients at very high fracture risk.

For most Mississippi patients with commercial insurance, Prolia offers a strong balance of proven efficacy, convenient dosing (twice yearly), and manageable cost after savings-card application. For Medicaid patients, generic alendronate or zoledronic acid remains the practical first-line choice given current formulary restrictions.

Patients initiating denosumab should have serum calcium and 25-hydroxyvitamin D levels checked before the first dose, with calcium supplementation of at least 1 to 000 mg and vitamin D of at least 1 to 000 IU daily maintained throughout treatment per the prescribing information [4].